Stock Details
3349.T is COSMOS Pharmaceutical Corporation's stock. Stock exchange Tokyo (Currency JPY). Average price in 50 days is 17,168.57¥. Average daily volumn in 3 months 161.99k. Market cap 752.38B



Stock symbol : 3349.T. Exchange : Tokyo. Currency : JPY
Lastest price : 19,000.00¥. Total volume : 136.80k. Market state POSTPOST
Click reload if you want to check the lastest price on market!!!

COSMOS Pharmaceutical Corporation (3349.T)
Last Price
19,000.00¥
Change
410.00
Volume
136.80k

Previous Close18,590.00
Open18,700.00
Day Range18,590.00-19,110.00
Bid19,000.00 x N/A
Ask19,040.00 x N/A
Volume136.8k
Average Volume161.99k
Market Cap752.38B
Beta0.27
52 Week Range14,710.00-19,740.00
Trailing P/E27.71
Foward P/E18.67
Dividend (Yield %)0.44%
Ex-Dividend Date2021-11-29



Financial Details


According to COSMOS Pharmaceutical Corporation's financial reports the company's revenue in 2021 were 726.42B an increase( +6.14%) over the years 2020 revenue that were of 684.4B. In 2021 the company's total earnings were 27.16B while total earnings in 2020 were 21.43B( +28.57%).


Loading ...



Organization

COSMOS Pharmaceutical Corporation operates a chain of drug stores in Japan. It also operates an online drug store. The company was founded in 1983 and is headquartered in Fukuoka, Japan.

Market Cap:
752.38B
Revenue:
726.42B
Total Assets:
341.32B
Total Cash:
55.11B


News about "COSMOS Pharmaceutical Corporation"

Cosmos Holdings CEO Greg Siokas Converts an Additional $1.25 Million of Debt into Common Stock ...

Cosmos Holdings, Inc. (“the Company”) (OTCQX: COSM ), an international pharmaceutical company with a proprietary line of branded and ...

Source from : Associated Press - 7 days ago


Cosmos Holdings Signs Exclusive Distribution Agreement with Mediprovita GbR for Launch of Sky Premium Life Products in Germany and Austria

CHICAGO, July 08, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (the “Company") (OTCQX: COSM), an international pharmaceutical company with a proprietary line of branded and generic ...

Source from : Yahoo Finance - 25 days ago


EQS-Adhoc: Cosmo Pharmaceuticals Announces Cassiopea SpA's Signing of License and Supply Agreements for Winlevi(R) in US and Canada_image

EQS-Adhoc: Cosmo Pharmaceuticals Announces Cassiopea SpA's Signing of License and Supply Agreements for Winlevi(R) in US and Canada

Agreement/Alliance Cosmo Pharmaceuticals Announces Cassiopea SpA's Signing of License and Supply Agreements for Win ...

Source from : Finanztreff - 7 days ago


Cosmos Holdings Inc

Cosmos Holdings Inc. operates as a pharmaceutical company. The Company identifies, acquires, develops, and commercializes generic pharmaceuticals, nutraceuticals, OTC medications, and medical ...

Source from : Bloomberg - 14 days ago


COSMOS Pharmaceutical Corp.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Source from : Barron's - 17 days ago


COSMO Pharmaceuticals N.V. Registered Shares (CMOPF)

Real-time Data is provided using Nasdaq Last Sale Data Market Cap (Capitalization) is a measure of the estimated value of the common equity securities of the company or their equivalent.

Source from : Nasdaq - 8 days ago


COSMO Pharmaceuticals NV

When autocomplete results are available use up and down arrows to review and enter to select. Touch device users, explore by touch or with swipe gestures.

Source from : Bloomberg - 10 days ago


Cosmo Half-Year Report 2021

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland - 30 July 2021 - Cosmo Pharmaceuticals N.V. (SIX: COPN) reports half-year results for the period ended 30 June 2021. Cosmo obtained the first ...

Source from : PharmiWeb - 3 days ago


Company Information

Dongguan Cosmos Plastic Products is a wholly owned subsidiary of Hong ... plastic processing and trading. Our company was established in 1997 and specializes in the R&D and production of PC blown-mold ...

Source from : Global Sources - 11 days ago


What’s in a COVID vaccine?

Most of the excipients have been approved food and pharmaceutical products for years ... Pfizer’s combination of lipids has been developed by a company called Acuitas, which has been researching ...

Source from : Cosmos - 14 days ago


GFCL, BP, Fuchs Compititors Are Going Up In Cutting Fluid Market- Updated Report Published By Market.Biz

Cutting Fluid Market 2021 Segments and Top Players- [GFCL, BP, Fuchs, Exxon Mobil Corporation, Yushiro Chemical, Quaker, Blaser, Blaser, Idemitsu Kosan, COSMO Oil, Master, JX NIPPON, Petrofer, KYODO ...

Source from : MarketWatch - 10 days ago


Ono Pharmaceutical Co. Ltd.

1 Day OPHLF 0.00% DJIA -0.86% S&P 500 -0.75% Health Care/Life Sciences -0.01% Gyo Sagara President & Representative Director Ono Pharmaceutical Co., Ltd. Toshihiro Tsujinaka Director & Managing ...

Source from : Wall Street Journal - 27 days ago


Cosmos Holdings CEO Greg Siokas Converts an Additional $1.25 Million of Debt into Common Stock at $6.00 Per Share

CHICAGO, July 26, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company”) (OTCQX: COSM), an international pharmaceutical company with a proprietary line of branded and generic ...

Source from : Yahoo Finance - 7 days ago


Cosmo Pharmaceuticals Announces Cassiopea SpA’s Signing of License and Supply Agreements for Winlevi® in US and Canada

Dublin, Ireland - 26 July 2021: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) announced today that Cassiopea SpA (SIX: SKIN), a company in which it holds 46.56% of the ordinary shares, has signed ...

Source from : PharmiWeb - 7 days ago


Ono Pharmaceutical Co. Ltd.

1 Day 4528 -0.70% DJIA -2.09% S&P 500 -1.59% Health Care/Life Sciences 0.84% Gyo Sagara President & Representative Director Ono Pharmaceutical Co., Ltd. Toshihiro Tsujinaka Director & Managing ...

Source from : Wall Street Journal - 13 days ago


Cosmos Holdings CEO Greg Siokas Converts an Additional $1.25 Million of Debt into Common Stock at $6.00 Per Share

CloseCurlyDoubleQuote; About Cosmos Holdings, Inc. Cosmos Holdings Inc. is an international pharmaceutical company, with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC ...

Source from : Stockhouse - 7 days ago


Cosmo Pharmaceuticals Announces Cassiopea SpA’s Signing of License and Supply Agreements for Winlevi® in US and Canada

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland - 26 July 2021: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) announced today that Cassiopea SpA (SIX: SKIN), a company in which it ...

Source from : Yahoo Finance - 7 days ago


Cosmos Holdings CEO Greg Siokas Converts an Additional $1.0 Million of Debt into Common Stock at $6.00 Per Share

CHICAGO, July 16, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM), an international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, ...

Source from : Yahoo Finance - 17 days ago


Cosmos Holdings CEO Greg Siokas Converts an Additional $1.25 Million of Debt into Common Stock at $6.00 Per Share

CEO has converted $4.0 million of the Company’s debt to date; the conversion price represents a premium to market CHICAGO, July 26, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company ...

Source from : wallstreet online - 7 days ago


Cosmos Holdings CEO Greg Siokas Converts an Additional $1.0 Million of Debt into Common Stock at $6.00 Per Share

CHICAGO, July 16, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM), an international pharmaceutical company with a proprietary line of branded and generic ...

Source from : wallstreet online - 17 days ago


Cosmos Holdings CEO Greg Siokas Converts $3.0 Million of Debt into Common Stock at $6.00 Per Share

CHICAGO, June 28, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. ("the Company") (OTCQX: COSM), an international pharmaceutical company with a proprietary line of branded and generic ...

Source from : Benzinga.com - 1 month ago


Cosmos Holdings Appoints Finance Veteran Alexi Papaconstantinou to its Advisory Board

CHICAGO, July 01, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM), an international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, ...

Source from : Yahoo Canada Sports - 1 month ago


Cosmos Holdings CEO Greg Siokas Converts $3.0 Million of Debt into Common Stock at $6.00 Per Share

CHICAGO, June 28, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM), an international pharmaceutical company with a proprietary line of branded and generic ...

Source from : Morningstar%2c Inc. - 1 month ago


Cosmos Holdings Appoints Finance Veteran Alexi Papaconstantinou to its Advisory Board

CHICAGO, July 01, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. ("the Company") (OTCQX: COSM), an international pharmaceutical company with a proprietary line of branded and generic ...

Source from : Benzinga.com - 1 month ago


R8,2-million Cosmo City Medical Centre launched

The Industrial Development Corporation (IDC) says that the opening of the R8,2-million Cosmo City Medical Centre is in line with its renewed focus on supporting projects in townships and rural areas.

Source from : Engineering News - 1 month ago


Cosmos Pharmaceutical Corp

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay May 15 (Reuters) - Cosmos Pharmaceutical Corp <3349.T>:Says it appoints Hideaki Yokoyama as president, to succeed Futoshi Shibata ...

Source from : Reuters - 1 year ago


COSMO Pharmaceuticals N.V. Registered Shares (CMOPF)

Nasdaq provides company’s SEC filings, which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC ...

Source from : Nasdaq - 1 year ago


Cosmos-Maya notches up its distribution focus with WowKidz Distribution; starts with massive acquisition slate for distribution in Asia Pacific

In a celebration of this spirit, Pharmaceutical company, Mankind Pharma has launched ‘anthem 2.0’ along with singer & music... Mumbai: Pidilite Industries Ltd on Thursday announced the ...

Source from : Indian Television Dot Com - 1 year ago


Cosmo Pharmaceu Regulatory News

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience. To access our Live RNS you must confirm you are a private ...

Source from : London South East - 2 years ago


Approval and Launch of New Products and High Prevalence of Cancer to Augment Growth of Opioid-Induced Constipation Treatment Market_image

Approval and Launch of New Products and High Prevalence of Cancer to Augment Growth of Opioid-Induced Constipation Treatment Market

Opioid induced constipation OIC is caused by prolonged use of certain opioids particularly for pain management OIC may also be caused by taking long term and excessive doses of narcotics with effects ...

Source from : openpr.com - 3 days ago


Inflammatory Bowel Disease Therapy Market Business Analysis, CAGR, Production, Rising Trends And Manufacturers Growth Outlook

Takeda Pharmaceutical Company, Abbott, Celgene Corporation, Innovate Biopharma, Cosmo Pharmaceuticals, Gilead Sciences, Pfizer Global Inflammatory Bowel Disease Therapy industrial report covers ...

Source from : Digital Journal - 6 days ago